Implant Sciences Signs TSA IDIQ Contract for Up to $162 M for Explosive Trace Detection Systems
- Indefinite Delivery - Indefinite Quantity Contract for QS-B220s
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has entered into an Indefinite Delivery / Indefinite Quantity (IDIQ) contract with the United States Transportation Security Administration (TSA) for its QS-B220 desktop explosives trace detectors, which recently received TSA qualification for airport checkpoint passenger and baggage screening. The IDIQ, a necessary prerequisite for competing for TSA's annual trace detection procurements, establishes contract terms under which the TSA could purchase up to $162 million of equipment and services.
"We are very pleased to receive an IDIQ of this magnitude from the TSA, just weeks after receiving approval for baggage and passenger screening. With this agreement, Implant Sciences becomes the first non-radioactive ETD manufacturer for passenger and baggage screening in airports. This is a testament to the performance and value delivered by our next-generation explosives trace detectors," stated Implant Sciences' CEO, Glenn D. Bolduc .
Unmanned Aerial Vehicle (UAV) Payloads & Subsystems Market Report 2016-2026
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
Mar 29 - 30, 2017 - London, United Kingdom